Skip to main content
OpenTrials
Completed

NCT Number: NCT00909467

Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases

Myelodysplastic and myeloproliferative Disease represent conditions with increased risk for pulmonary hypertension. However, the exact prevalence of pulmonary hypertension in these conditions is not known. The effects of pulmonary hypertension on the clinical picture and the symptoms of patients in these conditions needs also further exploration. This exploratory study is designed to describe the prevalence of pulmonary hypertension in the population with such hematologic diseases, and the stages of pulmonary hypertension as well its effect on exercise capacity at time of diagnosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myeloproliferative Disorder Bone Marrow Diseases Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hypertension Hypertension, Pulmonary Lung Diseases Myelodysplastic Syndromes Myeloproliferative Disorders Pulmonary Hypertension Respiratory Tract Diseases Vascular Diseases

Age range

18 year–95 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Medical University of Graz, Pulmonology

Graz, 8036, Austria

About this study

For early recognition of pulmonary hypertension exercise doppler echocardiography will be used in all patients. Patients with elevated pulmonary arterial pressure at rest or during exercise (estimated by echocardiography), or with decreased exercise capacity (as a potential sign of pulmonary hypertension) are advised to undergo right heart catheterisation. Cardiopulmonary exercise testing and six-minute walk distance measurement are performed to measure exercise capacity. The described work-up of patients allows precise and objective hemodynamic and clinical evaluation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • myelodysplastic disease or myeloproliferative diseases

Exclusion criteria

  • known pulmonary hypertension
  • relevant pulmonary disease
  • relevant left cardiac or valvular disease
  • recent major operations
  • recent changes in medications
  • relevant anaemia
  • inability to exercise

Treatment and study plan

echocardiography, right heart catheterisation

Other

at each patient an echocardiography will be performed at rest and during exercise. For the evaluation of exercise capacity, cardiopulmonary exercise testing and six-minute walk is performed. Right heart catheterisation is recommended to those with suspected pulmonary hypertension.

Other names: EDE, RHC

Primary outcomes

  1. mean pulmonary arterial pressure at rest and during exercise

    Time frame: at baseline and after 1 year

Secondary outcomes

  1. exercise capacity

    Time frame: at baseline and after 1 year

Sponsors and collaborators

Lead sponsor

Medical University of Graz

Other

Registry information

Important dates

Study start
2009
Primary completion
2011
Study completion
2011
First posted
May 28, 2009
Registry last updated
Mar 9, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.